Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Tomer Mark

Concepts (224)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Multiple Myeloma
47
2021
123
13.200
Why?
Thalidomide
17
2019
46
4.890
Why?
Antineoplastic Combined Chemotherapy Protocols
27
2021
1361
3.510
Why?
Hematopoietic Stem Cell Transplantation
21
2020
580
2.910
Why?
Dexamethasone
17
2021
318
2.410
Why?
Transplantation, Autologous
19
2021
205
2.210
Why?
Clarithromycin
8
2019
35
2.040
Why?
Transplantation Conditioning
10
2020
197
1.610
Why?
Plasma Cells
2
2017
64
1.330
Why?
Melphalan
5
2019
39
1.240
Why?
Antibodies, Monoclonal
11
2021
1263
1.020
Why?
Antineoplastic Agents, Immunological
3
2018
140
0.960
Why?
Salvage Therapy
3
2021
136
0.810
Why?
Boronic Acids
4
2013
37
0.800
Why?
Lymphoma
4
2021
175
0.770
Why?
Pyrazines
4
2013
76
0.760
Why?
Bortezomib
8
2021
46
0.740
Why?
Hematopoietic Stem Cell Mobilization
3
2015
20
0.700
Why?
Aged
39
2021
19627
0.690
Why?
Oligopeptides
1
2019
255
0.680
Why?
Transplants
1
2015
27
0.640
Why?
Induction Chemotherapy
1
2015
48
0.640
Why?
Clone Cells
1
2016
248
0.620
Why?
Recurrence
13
2020
977
0.620
Why?
Middle Aged
39
2021
28413
0.590
Why?
Survival Analysis
10
2019
1423
0.570
Why?
Stem Cell Transplantation
1
2014
146
0.550
Why?
Nitrogen Mustard Compounds
1
2013
6
0.540
Why?
Immunohistochemistry
2
2019
1862
0.540
Why?
Antineoplastic Agents
6
2020
2038
0.520
Why?
Immunosuppressive Agents
3
2016
855
0.520
Why?
Aged, 80 and over
14
2021
6682
0.510
Why?
Cord Blood Stem Cell Transplantation
3
2020
103
0.510
Why?
Humans
62
2021
108531
0.510
Why?
von Willebrand Diseases
1
2012
10
0.500
Why?
Adult
35
2021
31352
0.490
Why?
Angiogenesis Inhibitors
1
2014
213
0.490
Why?
Factor VIII
1
2012
53
0.490
Why?
von Willebrand Factor
1
2012
58
0.490
Why?
Neoplasm Recurrence, Local
6
2020
738
0.460
Why?
Clinical Trials as Topic
6
2017
1009
0.460
Why?
Pacemaker, Artificial
1
2012
115
0.450
Why?
Cell Proliferation
3
2019
2349
0.450
Why?
Proteasome Inhibitors
4
2020
45
0.410
Why?
Male
40
2021
59999
0.400
Why?
Cyclophosphamide
2
2013
234
0.400
Why?
Hematinics
1
2008
21
0.390
Why?
Immunologic Factors
4
2016
228
0.370
Why?
Immunoglobulins
1
2008
144
0.370
Why?
Female
38
2021
61452
0.370
Why?
Kaplan-Meier Estimate
7
2020
865
0.370
Why?
Granulocyte Colony-Stimulating Factor
4
2017
82
0.340
Why?
Bendamustine Hydrochloride
2
2019
12
0.340
Why?
Graft vs Host Disease
5
2020
231
0.330
Why?
Immunotherapy
2
2017
428
0.330
Why?
Antigens, CD34
4
2016
103
0.320
Why?
HLA Antigens
3
2016
233
0.320
Why?
Myeloablative Agonists
2
2015
27
0.300
Why?
Treatment Outcome
12
2019
8889
0.290
Why?
Haplotypes
2
2016
541
0.290
Why?
Disease-Free Survival
8
2021
671
0.280
Why?
Neoplasm Staging
6
2018
1209
0.260
Why?
Graft Survival
4
2017
396
0.250
Why?
Neoplasm, Residual
2
2020
81
0.240
Why?
Transplantation, Homologous
6
2021
502
0.220
Why?
Peripheral Blood Stem Cell Transplantation
2
2017
31
0.220
Why?
Leukemia, Myeloid, Acute
3
2016
434
0.220
Why?
In Situ Hybridization, Fluorescence
4
2020
332
0.210
Why?
Transplantation Chimera
2
2016
58
0.210
Why?
Combined Modality Therapy
4
2017
1203
0.200
Why?
Drug Therapy, Combination
4
2013
1018
0.200
Why?
Renal Insufficiency
2
2012
114
0.200
Why?
Follow-Up Studies
7
2020
4803
0.190
Why?
Mitotic Index
1
2017
29
0.180
Why?
Syndecan-1
1
2017
34
0.180
Why?
Retrospective Studies
11
2017
10533
0.180
Why?
Ki-67 Antigen
1
2017
116
0.180
Why?
Waldenstrom Macroglobulinemia
1
2016
8
0.170
Why?
ADP-ribosyl Cyclase 1
1
2016
35
0.170
Why?
Maximum Tolerated Dose
1
2017
183
0.170
Why?
Retreatment
2
2013
66
0.170
Why?
Primary Myelofibrosis
1
2016
9
0.170
Why?
Clinical Trials, Phase II as Topic
2
2013
56
0.170
Why?
Administration, Oral
1
2019
809
0.160
Why?
Immunoglobulin Light Chains
1
2015
34
0.160
Why?
Febrile Neutropenia
1
2015
2
0.160
Why?
Amyloidosis
1
2015
43
0.160
Why?
Thrombosis
2
2009
244
0.160
Why?
Levofloxacin
1
2015
29
0.160
Why?
Adjuvants, Immunologic
1
2017
240
0.150
Why?
Antineoplastic Agents, Alkylating
1
2015
75
0.150
Why?
Heterocyclic Compounds
1
2015
21
0.150
Why?
Survival Rate
5
2021
1783
0.150
Why?
Antibiotic Prophylaxis
1
2015
96
0.150
Why?
Prognosis
6
2019
3409
0.140
Why?
Daunorubicin
1
2013
27
0.140
Why?
Vidarabine
1
2013
26
0.140
Why?
Young Adult
10
2019
10690
0.140
Why?
Drug Evaluation, Preclinical
2
2017
199
0.140
Why?
Busulfan
1
2013
21
0.140
Why?
Databases, Factual
5
2016
1165
0.140
Why?
Cytarabine
1
2013
62
0.130
Why?
Bacteremia
1
2015
169
0.130
Why?
Remission Induction
2
2016
272
0.130
Why?
Protease Inhibitors
1
2013
111
0.130
Why?
Myeloma Proteins
2
2010
3
0.130
Why?
Drug Screening Assays, Antitumor
1
2013
184
0.130
Why?
Models, Biological
1
2021
1855
0.130
Why?
Desensitization, Immunologic
1
2014
99
0.130
Why?
Healthcare Disparities
1
2017
431
0.120
Why?
Lymphoma, Non-Hodgkin
1
2012
82
0.120
Why?
Risk Factors
4
2017
8746
0.120
Why?
Depsipeptides
1
2010
17
0.110
Why?
Biomarkers, Tumor
1
2017
999
0.110
Why?
Quality of Life
1
2021
1944
0.110
Why?
Hispanic Americans
1
2017
1085
0.110
Why?
Dose-Response Relationship, Drug
2
2013
2266
0.100
Why?
Antibodies, Monoclonal, Humanized
2
2017
605
0.100
Why?
Thrombocytopenia
2
2010
177
0.100
Why?
Bone Marrow Examination
1
2008
8
0.100
Why?
Antigens, Differentiation, B-Lymphocyte
1
2009
43
0.100
Why?
Registries
1
2017
1736
0.100
Why?
Histone Deacetylase Inhibitors
1
2010
186
0.100
Why?
Karyotyping
1
2008
131
0.100
Why?
Risk Assessment
2
2016
3080
0.100
Why?
Prospective Studies
4
2018
5921
0.100
Why?
Neoplastic Stem Cells
1
2013
336
0.100
Why?
Drug Administration Schedule
3
2018
848
0.090
Why?
Neutropenia
1
2007
130
0.090
Why?
Algorithms
1
2015
1555
0.090
Why?
Drug Resistance, Neoplasm
3
2018
652
0.090
Why?
Histocompatibility Antigens Class II
1
2009
322
0.090
Why?
Autografts
2
2017
30
0.090
Why?
Infusions, Intravenous
2
2018
446
0.080
Why?
Adolescent
7
2019
18140
0.080
Why?
Maintenance Chemotherapy
2
2016
26
0.080
Why?
Aspirin
1
2007
284
0.070
Why?
Filgrastim
2
2015
11
0.070
Why?
Randomized Controlled Trials as Topic
1
2009
1092
0.070
Why?
Stem Cells
1
2008
539
0.070
Why?
Alleles
2
2016
896
0.070
Why?
Abnormal Karyotype
1
2020
4
0.060
Why?
Disease Progression
2
2019
2433
0.050
Why?
Injection Site Reaction
1
2018
3
0.050
Why?
Incidence
2
2016
2359
0.050
Why?
Fetal Blood
1
2020
259
0.050
Why?
Drug Approval
1
2018
74
0.050
Why?
Acetates
1
2018
102
0.050
Why?
Quinolines
1
2018
122
0.050
Why?
Time Factors
3
2017
7105
0.050
Why?
Bone Marrow
1
2019
272
0.040
Why?
Allografts
1
2017
98
0.040
Why?
Risk
1
2020
950
0.040
Why?
Immunoglobulin A
1
2017
137
0.040
Why?
Cytogenetic Analysis
1
2016
30
0.040
Why?
Biomarkers
2
2019
3322
0.040
Why?
Histocompatibility Testing
1
2016
133
0.040
Why?
Lactate Dehydrogenases
1
2016
4
0.040
Why?
Splenomegaly
1
2016
17
0.040
Why?
Janus Kinase 2
1
2016
38
0.040
Why?
Neoplasms, Second Primary
1
2016
71
0.040
Why?
Karnofsky Performance Status
1
2015
40
0.040
Why?
Platelet Count
1
2015
93
0.040
Why?
Peripheral Nervous System Diseases
1
2016
141
0.040
Why?
Enterobacteriaceae
1
2015
38
0.040
Why?
Drug Resistance, Microbial
1
2015
73
0.040
Why?
Blood Cell Count
1
2015
61
0.040
Why?
Time-to-Treatment
1
2016
140
0.040
Why?
Animals
3
2017
34575
0.040
Why?
Granulocytes
1
2015
84
0.040
Why?
Enterobacteriaceae Infections
1
2015
36
0.040
Why?
Drug Resistance, Multiple, Bacterial
1
2015
67
0.040
Why?
Leukocyte Count
1
2015
324
0.040
Why?
Hematologic Diseases
1
2015
64
0.040
Why?
Drug Design
1
2016
177
0.040
Why?
Cohort Studies
2
2017
4757
0.040
Why?
Clostridium difficile
1
2015
59
0.040
Why?
Biopsy
1
2019
1077
0.040
Why?
Cause of Death
1
2016
372
0.040
Why?
Clostridium Infections
1
2015
58
0.040
Why?
Antifungal Agents
1
2015
148
0.040
Why?
Cell Lineage
1
2016
358
0.040
Why?
Tissue Donors
1
2016
297
0.040
Why?
Drug Synergism
1
2015
363
0.040
Why?
Testicular Neoplasms
1
2015
94
0.040
Why?
Mortality
1
2016
303
0.030
Why?
Case-Control Studies
2
2013
3310
0.030
Why?
Isoantibodies
1
2014
60
0.030
Why?
Molecular Targeted Therapy
1
2017
379
0.030
Why?
Cell Separation
1
2015
307
0.030
Why?
Clinical Protocols
1
2015
232
0.030
Why?
Clinical Trials, Phase I as Topic
1
2013
55
0.030
Why?
Immunocompromised Host
1
2015
216
0.030
Why?
Hematopoietic Stem Cells
1
2016
369
0.030
Why?
Graft Rejection
1
2016
598
0.030
Why?
Ethnic Groups
1
2017
663
0.030
Why?
Myelodysplastic Syndromes
1
2014
108
0.030
Why?
Length of Stay
1
2017
1025
0.030
Why?
United States
2
2018
11508
0.030
Why?
Recovery of Function
1
2015
592
0.030
Why?
Sex Factors
1
2017
1945
0.030
Why?
Neutrophils
1
2017
1176
0.030
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2014
234
0.030
Why?
European Continental Ancestry Group
1
2017
1357
0.030
Why?
Neoadjuvant Therapy
1
2013
229
0.030
Why?
African Americans
1
2017
1069
0.030
Why?
Guideline Adherence
1
2015
519
0.030
Why?
Flow Cytometry
1
2015
1168
0.030
Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
216
0.030
Why?
Cell Differentiation
1
2018
1735
0.030
Why?
Erythrocytes
1
2015
565
0.030
Why?
Feasibility Studies
1
2012
702
0.030
Why?
Recombinant Proteins
1
2013
1460
0.020
Why?
Bone and Bones
1
2010
243
0.020
Why?
Heparin, Low-Molecular-Weight
1
2007
27
0.020
Why?
Gene Expression Regulation, Neoplastic
1
2013
1163
0.020
Why?
Comorbidity
1
2012
1569
0.020
Why?
Practice Guidelines as Topic
1
2015
1546
0.020
Why?
Double-Blind Method
1
2010
1696
0.020
Why?
Creatinine
1
2007
437
0.020
Why?
Pain
1
2010
771
0.020
Why?
Age Factors
1
2012
3295
0.020
Why?
Severity of Illness Index
1
2012
2789
0.020
Why?
Signal Transduction
1
2013
4836
0.010
Why?
Mark's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)